SCHEMBL6086906

SCHEMBL6086906

O=S(=O)(Nc1cccc(-c2n[nH]cc2-c2nc3cc(-c4ccccc4)ccc3o2)c1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 18/20 0.60
PTPN5 P54829 18/20 0.60
PTPN2 P17706 16/20 0.60
MEN1 O00255 2/20 0.60
MAPT P10636 2/20 0.60
HPGD P15428 2/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
HSPD1 P10809 4/20 0.59
HSPE1 P61604 4/20 0.59
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085198 0.91 PTPN1 (0.61) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6085176 0.90 AGPAT2 (0.46) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6200297 0.87 PTPN1 (0.63) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6086345 0.85 MAPT (0.54) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6085204 0.84 PTPN1 (0.61) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6086112 0.84 PTPN1 (0.57) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6084550 0.83 AGPAT2 (0.54) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6085751 0.82 PTPN1 (0.71) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6202869 0.81 MAPT (0.58) PTPN1PTPN5PTPN2MEN1MAPT
SCHEMBL6084255 0.81 PTPN2 (0.58) PTPN1PTPN5PTPN2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 PTPN1 344/4885PTPN5 362/4885PTPN2 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.